Literature DB >> 15939817

Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias.

Antoine Ouvrard-Pascaud1, Yannis Sainte-Marie, Jean-Pierre Bénitah, Romain Perrier, Christelle Soukaseum, Aurelie Nguyen Dinh Cat, Anne Royer, Khai Le Quang, Flavien Charpentier, Sophie Demolombe, Fatima Mechta-Grigoriou, Ahmed T Beggah, Pierre Maison-Blanche, Marie-Edith Oblin, Claude Delcayre, Glenn I Fishman, Nicolette Farman, Brigitte Escoubet, Frederic Jaisser.   

Abstract

BACKGROUND: Life-threatening cardiac arrhythmia is a major source of mortality worldwide. Besides rare inherited monogenic diseases such as long-QT or Brugada syndromes, which reflect abnormalities in ion fluxes across cardiac ion channels as a final common pathway, arrhythmias are most frequently acquired and associated with heart disease. The mineralocorticoid hormone aldosterone is an important contributor to morbidity and mortality in heart failure, but its mechanisms of action are incompletely understood. METHODS AND
RESULTS: To specifically assess the role of the mineralocorticoid receptor (MR) in the heart, in the absence of changes in aldosteronemia, we generated a transgenic mouse model with conditional cardiac-specific overexpression of the human MR. Mice exhibit a high rate of death prevented by spironolactone, an MR antagonist used in human therapy. Cardiac MR overexpression led to ion channel remodeling, resulting in prolonged ventricular repolarization at both the cellular and integrated levels and in severe ventricular arrhythmias.
CONCLUSIONS: Our results indicate that cardiac MR triggers cardiac arrhythmias, suggesting novel opportunities for prevention of arrhythmia-related sudden death.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939817      PMCID: PMC3635833          DOI: 10.1161/CIRCULATIONAHA.104.503706

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

1.  Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.

Authors:  A F Lee; R J MacFadyen; A D Struthers
Journal:  Eur J Heart Fail       Date:  1999-12       Impact factor: 15.534

2.  Adverse cardiac effects of salt with fludrocortisone in hypertension.

Authors:  P O Lim; C A Farquharson; P Shiels; R T Jung; A D Struthers; T M MacDonald
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

3.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

4.  Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.

Authors:  F J Ramires; A Mansur; O Coelho; M Maranhão; C J Gruppi; C Mady; J A Ramires
Journal:  Am J Cardiol       Date:  2000-05-15       Impact factor: 2.778

5.  Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.

Authors:  K M Yee; S D Pringle; A D Struthers
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

6.  Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor.

Authors:  D Le Menuet; R Isnard; M Bichara; S Viengchareun; M Muffat-Joly; F Walker; M C Zennaro; M Lombès
Journal:  J Biol Chem       Date:  2001-08-08       Impact factor: 5.157

7.  Corticosteroid regulation of amiloride-sensitive sodium-channel subunit mRNA expression in mouse kidney.

Authors:  P MacDonald; S MacKenzie; L E Ramage; J R Seckl; R W Brown
Journal:  J Endocrinol       Date:  2000-04       Impact factor: 4.286

8.  Transgenic mice overexpressing human KvLQT1 dominant-negative isoform. Part II: Pharmacological profile.

Authors:  G Lande; S Demolombe; A Bammert; A Moorman; F Charpentier; D Escande
Journal:  Cardiovasc Res       Date:  2001-05       Impact factor: 10.787

9.  Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43.

Authors:  D E Gutstein; G E Morley; H Tamaddon; D Vaidya; M D Schneider; J Chen; K R Chien; H Stuhlmann; G I Fishman
Journal:  Circ Res       Date:  2001-02-16       Impact factor: 17.367

10.  A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects.

Authors:  Y Dor; T D Camenisch; A Itin; G I Fishman; J A McDonald; P Carmeliet; E Keshet
Journal:  Development       Date:  2001-05       Impact factor: 6.868

View more
  75 in total

Review 1.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 2.  Minireview: aldosterone biosynthesis: electrically gated for our protection.

Authors:  Nick A Guagliardo; Junlan Yao; Changlong Hu; Paula Q Barrett
Journal:  Endocrinology       Date:  2012-06-11       Impact factor: 4.736

Review 3.  Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.

Authors:  Mindy Markowitz; Frank Messineo; Neil L Coplan
Journal:  Clin Cardiol       Date:  2012-07-06       Impact factor: 2.882

4.  Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Authors:  Cristian A Amador; Jean-Philippe Bertocchio; Gwennan Andre-Gregoire; Sandrine Placier; Jean-Paul Duong Van Huyen; Soumaya El Moghrabi; Stefan Berger; David G Warnock; Christos Chatziantoniou; Iris Z Jaffe; Philippe Rieu; Frederic Jaisser
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

5.  Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia.

Authors:  Yannis Sainte Marie; Antoine Toulon; Ralf Paus; Eve Maubec; Aicha Cherfa; Maggy Grossin; Vincent Descamps; Maud Clemessy; Jean-Marie Gasc; Michel Peuchmaur; Adam Glick; Nicolette Farman; Frederic Jaisser
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

Review 6.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 7.  Aldosterone in heart disease.

Authors:  Anastasia S Mihailidou
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

8.  Eplerenone Reduces Atrial Fibrillation Burden Without Preventing Atrial Electrical Remodeling.

Authors:  Yoshio Takemoto; Rafael J Ramirez; Kuljeet Kaur; Oscar Salvador-Montañés; Daniela Ponce-Balbuena; Roberto Ramos-Mondragón; Steven R Ennis; Guadalupe Guerrero-Serna; Omer Berenfeld; José Jalife
Journal:  J Am Coll Cardiol       Date:  2017-12-12       Impact factor: 24.094

Review 9.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

10.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.